Literature DB >> 19866496

Genetic matters of CYP2D6 in breast cancer: copy number variations and nucleotide polymorphisms.

Ke-Da Yu, Zhi-Ming Shao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19866496     DOI： 10.1038/nrc2683-c1

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  12 in total

Review 1.  CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants.

Authors:  L DiAnne Bradford
Journal:  Pharmacogenomics       Date:  2002-03       Impact factor: 2.533

2.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real-time PCR.

Authors:  Elke Schaeffeler; Matthias Schwab; Michel Eichelbaum; Ulrich M Zanger
Journal:  Hum Mutat       Date:  2003-12       Impact factor: 4.878

3.  The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.

Authors:  Matthew P Goetz; Stacey K Knox; Vera J Suman; James M Rae; Stephanie L Safgren; Matthew M Ames; Daniel W Visscher; Carol Reynolds; Fergus J Couch; Wilma L Lingle; Richard M Weinshilboum; Emily G Barr Fritcher; Andrea M Nibbe; Zeruesenay Desta; Anne Nguyen; David A Flockhart; Edith A Perez; James N Ingle
Journal:  Breast Cancer Res Treat       Date:  2006-11-18       Impact factor: 4.872

4.  The 2988G>A polymorphism affects splicing of a CYP2D6 minigene.

Authors:  Thomas Rau; Silke Diepenbruck; Ines Diepenbruck; Thomas Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2006-11       Impact factor: 6.875

5.  Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.

Authors:  Claudia Toscano; Kathrin Klein; Julia Blievernicht; Elke Schaeffeler; Tanja Saussele; Sebastian Raimundo; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenet Genomics       Date:  2006-10       Impact factor: 2.089

Review 6.  Copy number variation: new insights in genome diversity.

Authors:  Jennifer L Freeman; George H Perry; Lars Feuk; Richard Redon; Steven A McCarroll; David M Altshuler; Hiroyuki Aburatani; Keith W Jones; Chris Tyler-Smith; Matthew E Hurles; Nigel P Carter; Stephen W Scherer; Charles Lee
Journal:  Genome Res       Date:  2006-06-29       Impact factor: 9.043

Review 7.  CYP2D6 and tamoxifen: DNA matters in breast cancer.

Authors:  Janelle M Hoskins; Lisa A Carey; Howard L McLeod
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

8.  Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism.

Authors:  J Gjerde; M Hauglid; H Breilid; S Lundgren; J E Varhaug; E R Kisanga; G Mellgren; V M Steen; E A Lien
Journal:  Ann Oncol       Date:  2007-10-18       Impact factor: 32.976

Review 9.  Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.

Authors:  Irma Meijerman; Linda M Sanderson; Paul H M Smits; Jos H Beijnen; Jan H M Schellens
Journal:  Drug Metab Rev       Date:  2007       Impact factor: 4.518

10.  Determination of cytochrome P450 2D6 (CYP2D6) gene copy number by real-time quantitative PCR.

Authors:  Laurent Bodin; Philippe H Beaune; Marie-Anne Loriot
Journal:  J Biomed Biotechnol       Date:  2005
View more
  7 in total

1.  Allelic and genotype frequencies of catechol-O-methyltransferase (Val158Met) and CYP2D6*10 (Pro34Ser) single nucleotide polymorphisms in the Philippines.

Authors:  Michael O Baclig; Rey Z Predicala; Cynthia A Mapua; Jingky P Lozano-Kühne; Maria Luisa G Daroy; Filipinas F Natividad; Francis O Javier
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

2.  Oncogenic pathways activated by pro-inflammatory cytokines promote mutant p53 stability: clue for novel anticancer therapies.

Authors:  Gabriella D'Orazi; Marco Cordani; Mara Cirone
Journal:  Cell Mol Life Sci       Date:  2020-10-17       Impact factor: 9.261

3.  Novel association strategy with copy number variation for identifying new risk Loci of human diseases.

Authors:  Xianfeng Chen; Xinlei Li; Ping Wang; Yang Liu; Zhenguo Zhang; Guoping Zhao; Haiming Xu; Jun Zhu; Xueying Qin; Suchao Chen; Landian Hu; Xiangyin Kong
Journal:  PLoS One       Date:  2010-08-20       Impact factor: 3.240

4.  CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic.

Authors:  Issa Dahabreh; Teruhiko Terasawa; Peter Castaldi; Thomas A Trikalinos
Journal:  PLoS Curr       Date:  2010-09-02

5.  Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression.

Authors:  Yu Mei; Wenya Linda Bi; James Agolia; Changchen Hu; Alexandra M Giantini Larsen; David M Meredith; Sally Al Abdulmohsen; Tejus Bale; Gavin P Dunn; Malak Abedalthagafi; Ian F Dunn
Journal:  Pituitary       Date:  2021-01-25       Impact factor: 4.107

6.  A general calculus of fitness landscapes finds genes under selection in cancers.

Authors:  Teng-Kuei Hsu; Jennifer Asmussen; Amanda Koire; Byung-Kwon Choi; Mayur A Gadhikar; Eunna Huh; Chih-Hsu Lin; Daniel M Konecki; Young Won Kim; Curtis R Pickering; Marek Kimmel; Lawrence A Donehower; Mitchell J Frederick; Jeffrey N Myers; Panagiotis Katsonis; Olivier Lichtarge
Journal:  Genome Res       Date:  2022-03-17       Impact factor: 9.438

7.  Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer.

Authors:  Qiwen Deng; Bangshun He; Tianyi Gao; Yuqin Pan; Huiling Sun; Yeqiong Xu; Rui Li; Houqun Ying; Feng Wang; Xian Liu; Jie Chen; Shukui Wang
Journal:  PLoS One       Date:  2014-07-24       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.